Translational Control of Metabolism and Cell Cycle Progression in Hepatocellular Carcinoma
Abstract
:1. Introduction
2. The Liver Is the Body Organ with the Highest Level of Protein Synthesis
3. Translation Basics and Its Crosstalk with Cancer
3.1. The Complex Basics of Translation
3.2. Translation Factors and Cancer, a Connection True for Many Tumor Types
3.3. The Nucleolus as an Additional Site of Tumorigenesis
3.4. HCC Oncogenic Mutations That Impact on Translation Factors
4. The Role of Ribosomal Factors in HCC Progression
4.1. The Ribosome
4.2. The Translation Factors
5. The Different Involvement of Translation Factors on the Basis of Etiology
5.1. Viral-Induced HCC
5.2. NAFLD-NASH Evolution to HCC
6. Concluding Remarks and Druggability
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Llovet, J.M.; Kelley, R.K.; Villanueva, A.; Singal, A.G.; Pikarsky, E.; Roayaie, S.; Lencioni, R.; Koike, K.; Zucman-Rossi, J.; Finn, R.S. Hepatocellular Carcinoma. Nat. Rev. Dis. Primers 2021, 7, 6. [Google Scholar] [CrossRef] [PubMed]
- Jorgensen, P.; Nishikawa, J.L.; Breitkreutz, B.-J.; Tyers, M. Systematic Identification of Pathways That Couple Cell Growth and Division in Yeast. Science 2002, 297, 395–400. [Google Scholar] [CrossRef]
- Holcik, M.; Sonenberg, N. Translational control in stress and apoptosis. Nat. Rev. Mol. Cell Biol. 2005, 6, 318–327. [Google Scholar] [CrossRef] [PubMed]
- BBlachier, M.; Leleu, H.; Peck-Radosavljevic, M.; Valla, D.C.; Roudot-Thoraval, F. The burden of liver disease in Europe: A review of available epidemiological data. J. Hepatol. 2013, 58, 593–608. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nemeth, E.; Ganz, T. Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis. Int. J. Mol. Sci. 2021, 22, 6493. [Google Scholar] [CrossRef] [PubMed]
- Jelkmann, W. The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur. J. Gastroenterol. Hepatol. 2001, 13, 791–801. [Google Scholar] [CrossRef]
- Arias, I.M.; Alter, H.J.; Boyer, J.L.; Cohen, D.E.; Shafritz, D.A.; Thorgeirsson, S.S.; Wolkoff, A.W. (Eds.) The Liver: Biology and Pathobiology; John Wiley & Sons: Hoboken, NJ, USA, 2020. [Google Scholar]
- Chedid, A.; Nair, V. Diurnal Rhythm in Endoplasmic Reticulum of Rat Liver: Electron Microscopic Study. Science 1972, 175, 176–179. [Google Scholar] [CrossRef]
- Fausto, N.; Campbell, J.S.; Riehle, K.J. Liver Regeneration. Hepatology 2006, 43, S45–S53. [Google Scholar] [CrossRef]
- Nevzorova, Y.A.; Tolba, R.; Trautwein, C.; Liedtke, C. Partial Hepatectomy in Mice. Lab. Anim. 2015, 49, 81–88. [Google Scholar] [CrossRef]
- Kimball, S.R.; Jefferson, L.S.; Nguyen, H.V.; Suryawan, A.; Bush, J.A.; Davis, T.A. Feeding Stimulates Protein Synthesis in Muscle and Liver of Neonatal Pigs through an Mtor-Dependent Process. Am. J. Physiol.-Endocrinol. Metab. 2000, 279, E1080–E1087. [Google Scholar] [CrossRef] [Green Version]
- Brina, D.; Miluzio, A.; Ricciardi, S.; Clarke, K.; Davidsen, P.K.; Viero, G.; Tebaldi, T.; Offenhäuser, N.; Rozman, J.; Rathkolb, B.; et al. eIF6 coordinates insulin sensitivity and lipid metabolism by coupling translation to transcription. Nat. Commun. 2015, 6, 8261. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kimball, S.R. Regulation of Global and Specific mRNA Translation by Amino Acids. J. Nutr. 2002, 132, 883–886. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ingolia, N.T. Ribosome Footprint Profiling of Translation throughout the Genome. Cell 2016, 165, 22–33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gerashchenko, M.V.; Peterfi, Z.; Yim, S.H.; Gladyshev, V.N. Translation elongation rate varies among organs and decreases with age. Nucleic Acids Res. 2020, 49, e9. [Google Scholar] [CrossRef]
- Gobet, C.; Weger, B.D.; Marquis, J.; Martin, E.; Neelagandan, N.; Gachon, F.; Naef, F. Robust Landscapes of Ribosome Dwell Times and Aminoacyl-Trnas in Response to Nutrient Stress in Liver. Proc. Natl. Acad. Sci. USA 2020, 117, 9630–9641. [Google Scholar] [CrossRef] [Green Version]
- Atger, F.; Gobet, C.; Marquis, J.; Martin, E.; Wang, J.; Weger, B.; Lefebvre, G.; Descombes, P.; Naef, F.; Gachon, F. Circadian and feeding rhythms differentially affect rhythmic mRNA transcription and translation in mouse liver. Proc. Natl. Acad. Sci. USA 2015, 112, E6579–E6588. [Google Scholar] [CrossRef] [Green Version]
- Shahbazian, F.M.; Jacobs, M.; Lajtha, A. Rates of Protein Synthesis in Brain and Other Organs. Int. J. Dev. Neurosci. 1987, 5, 39–42. [Google Scholar] [CrossRef]
- Lo, E.K.K.; Felicianna; Xu, J.-H.; Zhan, Q.; Zeng, Z.; El-Nezami, H. The Emerging Role of Branched-Chain Amino Acids in Liver Diseases. Biomedicines 2022, 10, 1444. [Google Scholar] [CrossRef]
- Bhat, M.; Robichaud, N.; Hulea, L.; Sonenberg, N.; Pelletier, J.; Topisirovic, I. Targeting the translation machinery in cancer. Nat. Rev. Drug Discov. 2015, 14, 261–278. [Google Scholar] [CrossRef]
- Loreni, F.; Mancino, M.; Biffo, S. Translation Factors and Ribosomal Proteins Control Tumor Onset and Progression: How? Oncogene 2014, 33, 2145–2156. [Google Scholar] [CrossRef] [Green Version]
- Robichaud, N.; Sonenberg, N.; Ruggero, D.; Schneider, R.J. Translational Control in Cancer. Cold Spring Harb. Perspect. Biol. 2019, 11, a032896. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Truitt, M.L.; Ruggero, D. New frontiers in translational control of the cancer genome. Nat. Rev. Cancer 2016, 16, 288–304. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schwanhäusser, B.; Busse, D.; Li, N.; Dittmar, G.; Schuchhardt, J.; Wolf, J.; Chen, W.; Selbach, M. Global quantification of mammalian gene expression control. Nature 2011, 473, 337–342. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Crick, F.H.C. On Protein Synthesis. Symp. Soc. Exp. Biol. Biol. Replication Macromol. 1958, XII, 138. [Google Scholar]
- Pradet-Balade, B.; Boulme, F.; Beug, H.; Mullner, E.W.; Garcia-Sanz, J.A. Translation Control: Bridging the Gap between Genomics and Proteomics? Trends Biochem. Sci. 2001, 26, 225–229. [Google Scholar] [CrossRef]
- Weber, R.; Ghoshdastider, U.; Spies, D.; Duré, C.; Valdivia-Francia, F.; Forny, M.; Ormiston, M.; Renz, P.F.; Taborsky, D.; Yigit, M.; et al. Monitoring the 5′UTR landscape reveals isoform switches to drive translational efficiencies in cancer. Oncogene 2022, 42, 638–650. [Google Scholar] [CrossRef]
- Cheng, Z.; Otto, G.M.; Powers, E.N.; Keskin, A.; Mertins, P.; Carr, S.A.; Jovanovic, M.; Brar, G.A. Pervasive, Coordinated Protein-Level Changes Driven by Transcript Isoform Switching during Meiosis. Cell 2018, 172, 910–923.e16. [Google Scholar] [CrossRef] [Green Version]
- Roux, P.P.; Topisirovic, I. Signaling Pathways Involved in the Regulation of mRNA Translation. Mol. Cell. Biol. 2018, 38, e00070-18. [Google Scholar] [CrossRef] [Green Version]
- Gandin, V.; Masvidal, L.; Cargnello, M.; Gyenis, L.; McLaughlan, S.; Cai, Y.; Tenkerian, C.; Morita, M.; Balanathan, P.; Jean-Jean, O.; et al. mTORC1 and CK2 coordinate ternary and eIF4F complex assembly. Nat. Commun. 2016, 7, 11127. [Google Scholar] [CrossRef] [Green Version]
- Ceci, M.; Gaviraghi, C.; Gorrini, C.; Sala, L.A.; Offenhäuser, N.; Marchisio, P.C.; Biffo, S. Release of eIF6 (p27BBP) from the 60S subunit allows 80S ribosome assembly. Nature 2003, 426, 579–584. [Google Scholar] [CrossRef]
- Lamper, A.M.; Fleming, R.H.; Ladd, K.M.; Lee, A.S.Y. A phosphorylation-regulated eIF3d translation switch mediates cellular adaptation to metabolic stress. Science 2020, 370, 853–856. [Google Scholar] [CrossRef] [PubMed]
- Hinnebusch, A.G. eIF3: A versatile scaffold for translation initiation complexes. Trends Biochem. Sci. 2006, 31, 553–562. [Google Scholar] [CrossRef] [PubMed]
- Fernandez Rodriguez, G.; Bianca, C.; Alessandro, F. Multiple Roles of M6a Rna Modification in Translational Regulation in Cancer. Int. J. Mol. Sci. 2022, 23, 8971. [Google Scholar] [CrossRef] [PubMed]
- Su, R.; Dong, L.; Li, Y.; Gao, M.; He, P.C.; Liu, W.; Wei, J.; Zhao, Z.; Gao, L.; Han, L.; et al. METTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis. Nature 2022, 24, 205–216. [Google Scholar] [CrossRef]
- Pelletier, J.; Sonenberg, N. The Organizing Principles of Eukaryotic Ribosome Recruitment. Annu. Rev. Biochem. 2019, 88, 307–335. [Google Scholar] [CrossRef] [PubMed]
- Basu, I.; Gorai, B.; Chandran, T.; Maiti, P.K.; Hussain, T. Selection of start codon during mRNA scanning in eukaryotic translation initiation. Commun. Biol. 2022, 5, 587. [Google Scholar] [CrossRef]
- Kozak, M. Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res. 1984, 12, 857–872. [Google Scholar] [CrossRef] [Green Version]
- Cao, X.; Slavoff, S.A. Non-AUG start codons: Expanding and regulating the small and alternative ORFeome. Exp. Cell Res. 2020, 391, 111973. [Google Scholar] [CrossRef]
- Kenner, L.R.; Anand, A.A.; Nguyen, H.C.; Myasnikov, A.G.; Klose, C.J.; McGeever, L.A.; Tsai, J.C.; Miller-Vedam, L.E.; Walter, P.; Frost, A. eIF2B-catalyzed nucleotide exchange and phosphoregulation by the integrated stress response. Science 2019, 364, 491–495. [Google Scholar] [CrossRef]
- Pavitt, G.D. Regulation of translation initiation factor eIF2B at the hub of the integrated stress response. Wiley Interdiscip. Rev. RNA 2018, 9, e1491. [Google Scholar] [CrossRef]
- Pestova, T.V.; Lomakin, I.B.; Lee, J.H.; Choi, S.K.; Dever, T.E.; Hellen, C.U.T. The joining of ribosomal subunits in eukaryotes requires eIF5B. Nature 2000, 403, 332–335. [Google Scholar] [CrossRef] [PubMed]
- de la Parra, C.; A Walters, B.; Geter, P.; Schneider, R.J. Translation initiation factors and their relevance in cancer. Curr. Opin. Genet. Dev. 2018, 48, 82–88. [Google Scholar] [CrossRef] [PubMed]
- Montalto, F.I.; De Amicis, F. Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. Cells 2020, 9, 2648. [Google Scholar] [CrossRef] [PubMed]
- Oberkersch, R.E.; Pontarin, G.; Astone, M.; Spizzotin, M.; Arslanbaeva, L.; Tosi, G.; Panieri, E.; Ricciardi, S.; Allega, M.F.; Brossa, A.; et al. Aspartate metabolism in endothelial cells activates the mTORC1 pathway to initiate translation during angiogenesis. Dev. Cell 2022, 57, 1241–1256.e8. [Google Scholar] [CrossRef]
- Manfrini, N.; Ricciardi, S.; Alfieri, R.; Ventura, G.; Calamita, P.; Favalli, A.; Biffo, S. Ribosome profiling unveils translational regulation of metabolic enzymes in primary CD4+ Th1 cells. Dev. Comp. Immunol. 2020, 109, 103697. [Google Scholar] [CrossRef]
- De Ponte Conti, B.; Miluzio, A.; Grassi, F.; Abrignani, S.; Biffo, S.; Ricciardi, S. Mtor-Dependent Translation Drives Tumor Infiltrating Cd8(+) Effector and Cd4(+) Treg Cells Expansion. Elife 2021, 10, e69015. [Google Scholar] [CrossRef]
- Miluzio, A.; Beugnet, A.; Grosso, S.; Brina, D.; Mancino, M.; Campaner, S.; Amati, B.; de Marco, A.; Biffo, S. Impairment of Cytoplasmic eIF6 Activity Restricts Lymphomagenesis and Tumor Progression without Affecting Normal Growth. Cancer Cell 2011, 19, 765–775. [Google Scholar] [CrossRef] [Green Version]
- Pelletier, J.; Graff, J.; Ruggero, D.; Sonenberg, N. Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development. Cancer Res. 2015, 75, 250–263. [Google Scholar] [CrossRef] [Green Version]
- Truitt, M.L.; Conn, C.S.; Shi, Z.; Pang, X.; Tokuyasu, T.; Coady, A.M.; Seo, Y.; Barna, M.; Ruggero, D. Differential Requirements for eIF4E Dose in Normal Development and Cancer. Cell 2015, 162, 59–71. [Google Scholar] [CrossRef] [Green Version]
- Wolfe, A.L.; Singh, K.; Zhong, Y.; Drewe, P.; Rajasekhar, V.K.; Sanghvi, V.R.; Mavrakis, K.J.; Jiang, M.; Roderick, J.E.; Van der Meulen, J.; et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature 2014, 513, 65–70. [Google Scholar] [CrossRef] [Green Version]
- Hsieh, A.C.; Costa, M.; Zollo, O.; Davis, C.; Feldman, M.E.; Testa, J.R.; Meyuhas, O.; Shokat, K.M.; Ruggero, D. Genetic Dissection of the Oncogenic Mtor Pathway Reveals Druggable Addiction to Translational Control Via 4ebp-Eif4e. Cancer Cell 2010, 17, 249–261. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van Riggelen, J.; Yetil, A.; Felsher, D.W. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat. Rev. Cancer 2010, 10, 301–309. [Google Scholar] [CrossRef] [PubMed]
- Miluzio, A.; Beugnet, A.; Volta, V.; Biffo, S. Eukaryotic initiation factor 6 mediates a continuum between 60S ribosome biogenesis and translation. EMBO Rep. 2009, 10, 459–465. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lafita-Navarro, M.C.; Conacci-Sorrell, M. Nucleolar Stress: From Development to Cancer. In Seminars in Cell & Developmental Biology; Academic Press: New York, NY, USA, 2022. [Google Scholar]
- Penzo, M.; Montanaro, L.; Treré, D.; Derenzini, M. The Ribosome Biogenesis—Cancer Connection. Cells 2019, 8, 55. [Google Scholar] [CrossRef] [Green Version]
- Chan, J.C.; Hannan, K.M.; Riddell, K.; Ng, P.Y.; Peck, A.; Lee, R.S.; Hung, S.; Astle, M.V.; Bywater, M.; Wall, M.; et al. AKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer. Sci. Signal. 2011, 4, ra56. [Google Scholar] [CrossRef]
- Donati, G.; Montanaro, L.; Derenzini, M. Ribosome Biogenesis and Control of Cell Proliferation: P53 Is Not Alonep53-Independent Control of Cell Proliferation. Cancer Res. 2012, 72, 1602–1607. [Google Scholar] [CrossRef] [Green Version]
- Iadevaia, V.; Liu, R.; Proud, C.G. Mtorc1 Signaling Controls Multiple Steps in Ribosome Biogenesis. In Seminars in Cell & Developmental Biology; Academic Press: New York, NY, USA, 2014. [Google Scholar]
- Liang, H.; Chen, X.; Yin, Q.; Ruan, D.; Zhao, X.; Zhang, C.; McNutt, M.A.; Yin, Y. PTENβ is an alternatively translated isoform of PTEN that regulates rDNA transcription. Nat. Commun. 2017, 8, 14771. [Google Scholar] [CrossRef] [Green Version]
- Catez, F.; Venezia, N.D.; Marcel, V.; Zorbas, C.; Lafontaine, D.L.J.; Diaz, J.-J. Ribosome biogenesis: An emerging druggable pathway for cancer therapeutics. Biochem. Pharmacol. 2019, 159, 74–81. [Google Scholar] [CrossRef] [Green Version]
- Gay, D.M.; Lund, A.H.; Jansson, M.D. Translational control through ribosome heterogeneity and functional specialization. Trends Biochem. Sci. 2021, 47, 66–81. [Google Scholar] [CrossRef]
- Volarevic, S.; Stewart, M.J.; Ledermann, B.; Zilberman, F.; Terracciano, L.; Montini, E.; Grompe, M.; Kozma, S.C.; Thomas, G. Proliferation, but Not Growth, Blocked by Conditional Deletion of 40s Ribosomal Protein S6. Science 2000, 288, 2045–2047. [Google Scholar] [CrossRef]
- Gufler, S.; Seeboeck, R.; Schatz, C.; Haybaeck, J. The Translational Bridge between Inflammation and Hepatocarcinogenesis. Cells 2022, 11, 533. [Google Scholar] [CrossRef] [PubMed]
- Meyuhas, O. Ribosomal Protein S6 Phosphorylation: Four Decades of Research. Int. Rev. Cell Mol. Biol. 2015, 320, 41–73. [Google Scholar] [PubMed]
- Bohlen, J.; Roiuk, M.; A Teleman, A. Phosphorylation of ribosomal protein S6 differentially affects mRNA translation based on ORF length. Nucleic Acids Res. 2021, 49, 13062–13074. [Google Scholar] [CrossRef] [PubMed]
- Lara, R.; Seckl, M.J.; Pardo, O.E. The P90 Rsk Family Members: Common Functions and Isoform Specificityp90 Rsk Family in Cancer: Functions and Isoform Specificity. Cancer Res. 2013, 73, 5301–5308. [Google Scholar] [CrossRef] [Green Version]
- Wang, W.; Pan, Q.; Fuhler, G.M.; Smits, R.; Peppelenbosch, M.P. Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. J. Gastroenterol. 2016, 52, 419–431. [Google Scholar] [CrossRef] [Green Version]
- Kawate, S.; Fukusato, T.; Ohwada, S.; Watanuki, A.; Morishita, Y. Amplification of C-Myc in Hepatocellular Carcinoma: Correlation with Clinicopathologic Features, Proliferative Activity and P53 Overexpression. Oncology 1999, 57, 157–163. [Google Scholar] [CrossRef]
- Ruggero, D. The Role of Myc-Induced Protein Synthesis in Cancerthe Role of Myc-Induced Protein Synthesis in Cancer. Cancer Res. 2009, 69, 8839–8843. [Google Scholar] [CrossRef] [Green Version]
- Xu, Y.; Poggio, M.; Jin, H.Y.; Shi, Z.; Forester, C.M.; Wang, Y.; Stumpf, C.R.; Xue, L.; Devericks, E.; So, L.; et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat. Med. 2019, 25, 301–311. [Google Scholar] [CrossRef]
- Xie, X.; Guo, P.; Yu, H.; Wang, Y.; Chen, G. Ribosomal proteins: Insight into molecular roles and functions in hepatocellular carcinoma. Oncogene 2017, 37, 277–285. [Google Scholar] [CrossRef]
- Shimizu, K.; Izumi, R.; Ii, T.; Muraoka, K.; Inoue, T.; Fukushima, W.; Sakamoto, K.; Tani, T.; Hashimoto, T.; Yagi, M. Prognostic significance of nucleolar organizer regions in hepatocellular carcinoma. Hepatology 1995, 21, 393–397. [Google Scholar] [CrossRef]
- Wu, C.; Xia, D.; Wang, D.; Wang, S.; Sun, Z.; Xu, B.; Zhang, D. TCOF1 coordinates oncogenic activation and rRNA production and promotes tumorigenesis in HCC. Cancer Sci. 2021, 113, 553–564. [Google Scholar] [CrossRef] [PubMed]
- Gallo, S.; Ricciardi, S.; Manfrini, N.; Pesce, E.; Oliveto, S.; Calamita, P.; Mancino, M.; Maffioli, E.; Moro, M.; Crosti, M.; et al. RACK1 Specifically Regulates Translation through Its Binding to Ribosomes. Mol. Cell. Biol. 2018, 38, e00230-18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Volta, V.; Beugnet, A.; Gallo, S.; Magri, L.; Brina, D.; Pesce, E.; Calamita, P.; Sanvito, F.; Biffo, S. RACK1 depletion in a mouse model causes lethality, pigmentation deficits and reduction in protein synthesis efficiency. Cell. Mol. Life Sci. 2012, 70, 1439–1450. [Google Scholar] [CrossRef]
- Romano, N.; Di Giacomo, B.; Nobile, V.; Borreca, A.; Willems, D.; Tilesi, F.; Catalani, E.; Agrawal, M.; Welshhans, K.; Ricciardi, S.; et al. Ribosomal RACK1 Regulates the Dendritic Arborization by Repressing FMRP Activity. Int. J. Mol. Sci. 2022, 23, 11857. [Google Scholar] [CrossRef] [PubMed]
- Ruan, Y.; Sun, L.; Hao, Y.; Wang, L.; Xu, J.; Zhang, W.; Xie, J.; Guo, L.; Zhou, L.; Yun, X.; et al. Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J. Clin. Investig. 2012, 122, 2554–2566. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cao, J.; Zhao, M.; Liu, J.; Zhang, X.; Pei, Y.; Wang, J.; Yang, X.; Shen, B.; Zhang, J. RACK1 Promotes Self-Renewal and Chemoresistance of Cancer Stem Cells in Human Hepatocellular Carcinoma through Stabilizing Nanog. Theranostics 2019, 9, 811–828. [Google Scholar] [CrossRef] [PubMed]
- Yang, M.; Zhou, Y.; Deng, H.; Zhou, H.; Cheng, S.; Zhang, D.; He, X.; Mai, L.; Chen, Y.; Chen, J. Ribosomal Protein L23 Drives the Metastasis of Hepatocellular Carcinoma via Upregulating MMP9. Front. Oncol. 2021, 11, 779748. [Google Scholar] [CrossRef]
- Shi, Y.; Wang, X.; Zhu, Q.; Chen, G. The Ribosomal Protein L28 Gene Induces Sorafenib Resistance in Hepatocellular Carcinoma. Front. Oncol. 2021, 11, 685694. [Google Scholar] [CrossRef]
- Kim, J.H.; You, K.R.; Kim, I.H.; Cho, B.H.; Kim, C.Y.; Kim, D.G. Over-Expression of the Ribosomal Protein L36a Gene Is Associated with Cellular Proliferation in Hepatocellular Carcinoma. Hepatology 2004, 39, 129–138. [Google Scholar] [CrossRef]
- Montanaro, L.; Treré, D.; Derenzini, M. Nucleolus, Ribosomes, and Cancer. Am. J. Pathol. 2008, 173, 301–310. [Google Scholar] [CrossRef] [Green Version]
- Lohrum, M.A.; Ludwig, R.L.; Kubbutat, M.H.; Hanlon, M.; Vousden, K.H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003, 3, 577–587. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fabbri, L.; Chakraborty, A.; Robert, C.; Vagner, S. The plasticity of mRNA translation during cancer progression and therapy resistance. Nat. Rev. Cancer 2021, 21, 558–577. [Google Scholar] [CrossRef] [PubMed]
- Wang, C.; Cigliano, A.; Jiang, L.; Li, X.; Fan, B.; Pilo, M.G.; Liu, Y.; Gui, B.; Sini, M.; Smith, J.W.; et al. 4ebp1/Eif4e and P70s6k/Rps6 Axes Play Critical and Distinct Roles in Hepatocarcinogenesis Driven by Akt and N-Ras Proto-Oncogenes in Mice. Hepatology 2015, 61, 200–213. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kimball, S.R.; Karinch, A.M.; Feldhoff, R.C.; Mellor, H.; Jefferson, L.S. Purification and characterization of eukaryotic translational initiation factor eIF-2B from liver. Biochim. et Biophys. Acta (BBA)—Gen. Subj. 1994, 1201, 473–481. [Google Scholar] [CrossRef]
- Schreier, M.H.; Staehelin, T. Initiation of Eukaryotic Protein Synthesis: [Met-tRNAf.40S Ribosome] Initiation Complex Catalysed by Purified Initiation Factors in the Absence of mRNA. Nat. New Biol. 1973, 242, 35–38. [Google Scholar] [CrossRef]
- Golob-Schwarzl, N.; Krassnig, S.; Toeglhofer, A.M.; Park, Y.N.; Gogg-Kamerer, M.; Vierlinger, K.; Schröder, F.; Rhee, H.; Schicho, R.; Fickert, P.; et al. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. Eur. J. Cancer 2017, 83, 56–70. [Google Scholar] [CrossRef]
- Uhlén, M.; Zhang, C.; Lee, S.; Sjöstedt, E.; Fagerberg, L.; Bidkhori, G.; Benfeitas, R.; Arif, M.; Liu, Z.; Edfors, F.; et al. A pathology atlas of the human cancer transcriptome. Science 2017, 357, eaan2507. [Google Scholar] [CrossRef] [Green Version]
- Scagliola, A.; Miluzio, A.; Ventura, G.; Oliveto, S.; Cordiglieri, C.; Manfrini, N.; Cirino, D.; Ricciardi, S.; Valenti, L.; Baselli, G.; et al. Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma. Nat. Commun. 2021, 12, 4878. [Google Scholar] [CrossRef]
- Scagliola, A.; Miluzio, A.; Mori, G.; Ricciardi, S.; Oliveto, S.; Manfrini, N.; Biffo, S. Inhibition of eIF6 Activity Reduces Hepatocellular Carcinoma Growth: An In Vivo and In Vitro Study. Int. J. Mol. Sci. 2022, 23, 7720. [Google Scholar] [CrossRef]
- Sun, L.; Liu, S.; Wang, X.; Zheng, X.; Chen, Y.; Shen, H. eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway. J. Transl. Med. 2021, 19, 216. [Google Scholar] [CrossRef]
- Fu, S.; Fan, J.; Blanco, J.; Giménez-Cassina, A.; Danial, N.N.; Watkins, S.M.; Hotamisligil, G.S. Polysome Profiling in Liver Identifies Dynamic Regulation of Endoplasmic Reticulum Translatome by Obesity and Fasting. PLoS Genet. 2012, 8, e1002902. [Google Scholar] [CrossRef] [PubMed]
- Zou, Q.; Xiao, Z.; Huang, R.; Wang, X.; Wang, X.; Zhao, H.; Yang, X. Survey of the translation shifts in hepatocellular carcinoma with ribosome profiling. Theranostics 2019, 9, 4141–4155. [Google Scholar] [CrossRef] [PubMed]
- Kaur, H.; Bhalla, S.; Kaur, D.; Raghava, G.P. CancerLivER: A database of liver cancer gene expression resources and biomarkers. Database 2020, 2020, baaa012. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ahrens, M.; Ammerpohl, O.; von Schönfels, W.; Kolarova, J.; Bens, S.; Itzel, T.; Teufel, A.; Herrmann, A.; Brosch, M.; Hinrichsen, H.; et al. DNA Methylation Analysis in Nonalcoholic Fatty Liver Disease Suggests Distinct Disease-Specific and Remodeling Signatures after Bariatric Surgery. Cell Metab. 2013, 18, 296–302. [Google Scholar] [CrossRef] [Green Version]
- Baselli, G.A.; Dongiovanni, P.; Rametta, R.; Meroni, M.; Pelusi, S.; Maggioni, M.; Badiali, S.; Pingitore, P.; Maurotti, S.; Montalcini, T.; et al. Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut 2020, 69, 1855–1866. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moylan, C.A.; Pang, H.; Dellinger, A.; Suzuki, A.; Garrett, M.E.; Guy, C.D.; Murphy, S.K.; Ashley-Koch, A.E.; Choi, S.S.; Michelotti, G.A.; et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology 2013, 59, 471–482. [Google Scholar] [CrossRef] [Green Version]
- Suppli, M.P.; Rigbolt, K.T.G.; Veidal, S.S.; Heebøll, S.; Eriksen, P.L.; Demant, M.; Bagger, J.I.; Nielsen, J.; Oró, D.; Thrane, S.W.; et al. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. Am. J. Physiol. Gastrointest. Liver Physiol. 2019, 316, G462–G472. [Google Scholar] [CrossRef]
- Fujiwara, N.; Kubota, N.; Crouchet, E.; Koneru, B.; Marquez, C.A.; Jajoriya, A.K.; Panda, G.; Qian, T.; Zhu, S.; Goossens, N.; et al. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Sci. Transl. Med. 2022, 14, eabo4474. [Google Scholar] [CrossRef]
- Wang, X.-L.; Cai, H.-P.; Ge, J.-H.; Su, X.-F. Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma. World J. Gastroenterol. 2012, 18, 2540–2544. [Google Scholar] [CrossRef]
- Zhang, L.; Chen, Y.; Bao, C.; Zhang, X.; Li, H. Eukaryotic Initiation Factor 4aiii Facilitates Hepatocellular Carcinoma Cell Proliferation, Migration, and Epithelial-Mesenchymal Transition Process Via Antagonistically Binding to Wd Repeat Domain 66 with Mirna-2113. J. Cell. Physiol. 2020, 235, 8199–8209. [Google Scholar] [CrossRef]
- Wang, Z.-G.; Zheng, H.; Gao, W.; Han, J.; Cao, J.-Z.; Yang, Y.; Li, S.; Gao, R.; Liu, H.; Pan, Z.-Y.; et al. eIF5B increases ASAP1 expression to promote HCC proliferation and invasion. Oncotarget 2016, 7, 62327–62339. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, Y.W.; Lin, K.T.; Chen, S.C.; Gu, D.L.; Chen, C.F.; Tu, P.H.; Jou, Y.S. Overexpressed-Eif3i Interacted and Activated Oncogenic Akt1 Is a Theranostic Target in Human Hepatocellular Carcinoma. Hepatology 2013, 58, 239–250. [Google Scholar] [CrossRef] [PubMed]
- Li, S.; Shao, J.; Lou, G.; Wu, C.; Liu, Y.; Zheng, M. MiR-144-3p-mediated dysregulation of EIF4G2 contributes to the development of hepatocellular carcinoma through the ERK pathway. J. Exp. Clin. Cancer Res. 2021, 40, 53. [Google Scholar] [CrossRef]
- Xiong, X.; Kuang, H.; Liu, T.; Lin, J.D. A Single-Cell Perspective of the Mammalian Liver in Health and Disease. Hepatology 2020, 71, 1467–1473. [Google Scholar] [CrossRef] [PubMed]
- Ramachandran, P.; Dobie, R.; Wilson-Kanamori, J.R.; Dora, E.F.; Henderson, B.E.P.; Luu, N.T.; Portman, J.R.; Matchett, K.P.; Brice, M.; Marwick, J.A.; et al. Resolving the Fibrotic Niche of Human Liver Cirrhosis at Single-Cell Level. Nature 2019, 575, 512–518. [Google Scholar] [CrossRef]
- Lu, Y.; Yang, A.; Quan, C.; Pan, Y.; Zhang, H.; Li, Y.; Gao, C.; Lu, H.; Wang, X.; Cao, P.; et al. A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma. Nat. Commun. 2022, 13, 4594. [Google Scholar] [CrossRef] [PubMed]
- Massalha, H.; Halpern, K.B.; Abu-Gazala, S.; Jana, T.; E Massasa, E.; E Moor, A.; Buchauer, L.; Rozenberg, M.; Pikarsky, E.; Amit, I.; et al. A single cell atlas of the human liver tumor microenvironment. Mol. Syst. Biol. 2020, 16, e9682. [Google Scholar] [CrossRef]
- Otto, G.A.; Puglisi, J.D. The Pathway of HCV IRES-Mediated Translation Initiation. Cell 2004, 119, 369–380. [Google Scholar] [CrossRef] [Green Version]
- Brown, Z.P.; Abaeva, I.S.; De, S.; Hellen, C.U.T.; Pestova, T.V.; Frank, J. Molecular architecture of 40S translation initiation complexes on the hepatitis C virus IRES. EMBO J. 2022, 41, e110581. [Google Scholar] [CrossRef]
- Godet, A.C.; David, F.; Hantelys, F.; Tatin, F.; Lacazette, E.; Garmy-Susini, B.; Prats, A.C. Ires Trans-Acting Factors, Key Actors of the Stress Response. Int. J. Mol. Sci. 2019, 20, 924. [Google Scholar] [CrossRef] [Green Version]
- González-Almela, E.; Williams, H.; Sanz, M.A.; Carrasco, L. The Initiation Factors eIF2, eIF2A, eIF2D, eIF4A, and eIF4G Are Not Involved in Translation Driven by Hepatitis C Virus IRES in Human Cells. Front. Microbiol. 2018, 9, 207. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bracic Tomazic, S.; Schatz, C.; Haybaeck, J. Translational Regulation in Hepatocellular Carcinogenesis. Drug Des. Dev. Ther. 2021, 15, 4359–4369. [Google Scholar] [CrossRef] [PubMed]
- Zhu, Q.; Qiao, G.L.; Zeng, X.C.; Li, Y.; Yan, J.J.; Duan, R.; Du, Z.Y. Elevated Expression of Eukaryotic Translation Initiation Factor 3 h Is Associated with Proliferation, Invasion and Tumorigenicity in Human Hepatocellular Carcinoma. Oncotarget 2016, 7, 49888. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marrero, J.A.; Kulik, L.M.; Sirlin, C.B.; Zhu, A.X.; Finn, R.S.; Abecassis, M.M.; Roberts, L.R.; Heimbach, J.K. Diagnosis, S Taging, and M Anagement of H Epatocellular C Arcinoma: 2018 P Ractice G Uidance by the a Merican a Ssociation for the S Tudy of L Iver D Iseases. Hepatology 2018, 68, 723–750. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, D.Q.; El-Serag, H.B.; Loomba, R. Global Epidemiology of Nafld-Related Hcc: Trends, Predictions, Risk Factors and Prevention. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 223–238. [Google Scholar] [CrossRef]
- Friedman, S.L.; Neuschwander-Tetri, B.A.; Rinella, M.; Sanyal, A.J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 2018, 24, 908–922. [Google Scholar] [CrossRef]
- Stine, J.G.; Wentworth, B.J.; Zimmet, A.; Rinella, M.E.; Loomba, R.; Caldwell, S.H.; Argo, C.K. Systematic review with meta-analysis: Risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment. Pharmacol. Ther. 2018, 48, 696–703. [Google Scholar] [CrossRef]
- Chen, Z.; Tian, R.; She, Z.; Cai, J.; Li, H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic. Biol. Med. 2020, 152, 116–141. [Google Scholar] [CrossRef]
- Kim, Y.S.; Kim, S.G. Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases. Clin. Mol. Hepatol. 2020, 26, 715–727. [Google Scholar] [CrossRef]
- Sánchez, P.S.; Rigual, M.D.M.; Djouder, N. Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development. Cancers 2021, 13, 5045. [Google Scholar] [CrossRef]
- Li, X.; Ramadori, P.; Pfister, D.; Seehawer, M.; Zender, L.; Heikenwalder, M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat. Rev. Cancer 2021, 21, 541–557. [Google Scholar] [CrossRef] [PubMed]
- Patel, P.S.; Pérez-Baos, S.; Walters, B.; Orlen, M.; Volkova, A.; Ruggles, K.; Park, C.Y.; Schneider, R.J. Translational regulation of TFH cell differentiation and autoimmune pathogenesis. Sci. Adv. 2022, 8, eabo1782. [Google Scholar] [CrossRef] [PubMed]
- Ricciardi, S.; Manfrini, N.; Alfieri, R.; Calamita, P.; Crosti, M.C.; Gallo, S.; Müller, R.; Pagani, M.; Abrignani, S.; Biffo, S. The Translational Machinery of Human Cd4(+) T Cells Is Poised for Activation and Controls the Switch from Quiescence to Metabolic Remodeling. Cell Metab. 2018, 28, 895–906.e5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Biffo, S.; Manfrini, N.; Ricciardi, S. Crosstalks between Translation and Metabolism in Cancer. Curr. Opin. Genet. Dev. 2018, 48, 75–81. [Google Scholar] [CrossRef]
- Leibovitch, M.; Topisirovic, I. Dysregulation of mRNA translation and energy metabolism in cancer. Adv. Biol. Regul. 2017, 67, 30–39. [Google Scholar] [CrossRef] [PubMed]
- Dai, X.; Zhu, M. Coupling of Ribosome Synthesis and Translational Capacity with Cell Growth. Trends Biochem. Sci. 2020, 45, 681–692. [Google Scholar] [CrossRef] [PubMed]
- Conn, C.S.; Yang, H.; Tom, H.J.; Ikeda, K.; Oses-Prieto, J.A.; Vu, H.; Oguri, Y.; Nair, S.; Gill, R.M.; Kajimura, S.; et al. The major cap-binding protein eIF4E regulates lipid homeostasis and diet-induced obesity. Nat. Metab. 2021, 3, 244–257. [Google Scholar] [CrossRef]
- Jin, X.; Yu, R.; Wang, X.; Proud, C.G.; Jiang, T. Progress in Developing Mnk Inhibitors. Eur. J. Med. Chem. 2021, 219, 113420. [Google Scholar] [CrossRef]
- Gandin, V.; Miluzio, A.; Barbieri, A.M.; Beugnet, A.; Kiyokawa, H.; Marchisio, P.C.; Biffo, S. Eukaryotic Initiation Factor 6 Is Rate-Limiting in Translation, Growth and Transformation. Nature 2008, 455, 684–688. [Google Scholar] [CrossRef] [Green Version]
- Sfakianos, A.P.; Raven, R.M.; Willis, A.E. The pleiotropic roles of eIF5A in cellular life and its therapeutic potential in cancer. Biochem. Soc. Trans. 2022, 50, 1885–1895. [Google Scholar] [CrossRef]
- Zhou, J.; Pang, J.; Tripathi, M.; Ho, J.P.; Widjaja, A.A.; Shekeran, S.G.; Cook, S.A.; Suzuki, A.; Diehl, A.M.; Petretto, E.; et al. Spermidine-mediated hypusination of translation factor EIF5A improves mitochondrial fatty acid oxidation and prevents non-alcoholic steatohepatitis progression. Nat. Commun. 2022, 13, 5202. [Google Scholar] [CrossRef] [PubMed]
- Lee, N.P.; Tsang, F.H.; Shek, F.H.; Mao, M.; Dai, H.; Zhang, C.; Dong, S.; Guan, X.-Y.; Poon, R.T.; Luk, J.M. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. Int. J. Cancer 2009, 127, 968–976. [Google Scholar] [CrossRef] [PubMed]
- Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Ducreux, M.; Kim, T.-Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.O.; et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 2020, 382, 1894–1905. [Google Scholar] [CrossRef]
- Khoo, T.S.W.L.; Rehman, A.; Olynyk, J.K. Tyrosine Kinase Inhibitors in the Treatment of Hepatocellular Carcinoma. In Hepatocellular Carcinoma; Codon Publications: Delhi, India, 2019; pp. 127–139. [Google Scholar]
- Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; De Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; et al. Sorafenib in Advanced Hepatocellular Carcinoma. N. Engl. J. Med. 2008, 359, 378–390. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Abou-Alfa, G.K.; Meyer, T.; Cheng, A.-L.; El-Khoueiry, A.B.; Rimassa, L.; Ryoo, B.-Y.; Cicin, I.; Merle, P.; Chen, Y.; Park, J.-W.; et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N. Engl. J. Med. 2018, 379, 54–63. [Google Scholar] [CrossRef] [PubMed]
- Jefferies, H.B.J.; Fumagalli, S.; Dennis, P.B.; Reinhard, C.; Pearson, R.B.; Thomas, G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J. 1997, 16, 3693–3704. [Google Scholar] [CrossRef] [Green Version]
- Gedaly, R.; Angulo, P.; Hundley, J.; Daily, M.F.; Chen, C.; Koch, A.; Evers, B.M. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer. Res. 2010, 30, 4951–4958. [Google Scholar]
- Fang, C.; Xie, H.; Zhao, J.; Wang, W.; Hou, H.; Zhang, B.; Zhou, D.; Geng, X. eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma. Anti-Cancer Drugs 2021, 32, 822–828. [Google Scholar] [CrossRef]
- Derenzini, M.; Montanaro, L.; Trerè, D. Ribosome biogenesis and cancer. Acta Histochem. 2017, 119, 190–197. [Google Scholar] [CrossRef]
- Cabral, L.K.D.; Tiribelli, C.; Sukowati, C.H.C. Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. Cancers 2020, 12, 1576. [Google Scholar] [CrossRef]
- Laham-Karam, N.; Pinto, G.P.; Poso, A.; Kokkonen, P. Transcription and Translation Inhibitors in Cancer Treatment. Front. Chem. 2020, 8, 276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ueda, T.; Watanabe-Fukunaga, R.; Fukuyama, H.; Nagata, S.; Fukunaga, R. Mnk2 and Mnk1 Are Essential for Constitutive and Inducible Phosphorylation of Eukaryotic Initiation Factor 4E but Not for Cell Growth or Development. Mol. Cell. Biol. 2004, 24, 6539–6549. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pal, I.; Safari, M.; Jovanovic, M.; Bates, S.E.; Deng, C. Targeting Translation of mRNA as a Therapeutic Strategy in Cancer. Curr. Hematol. Malign-Rep. 2019, 14, 219–227. [Google Scholar] [CrossRef] [PubMed]
- Moon, S.L.; Sonenberg, N.; Parker, R. Neuronal Regulation of eIF2α Function in Health and Neurological Disorders. Trends Mol. Med. 2018, 24, 575–589. [Google Scholar] [CrossRef]
- Yamada, S.-I.; Ohira, M.; Horie, H.; Ando, K.; Takayasu, H.; Suzuki, Y.; Sugano, S.; Hirata, T.; Goto, T.; Matsunaga, T.; et al. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: Identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 2004, 23, 5901–5911. [Google Scholar] [CrossRef] [Green Version]
- Li, L.; Halpert, G.; Lerner, M.G.; Hu, H.; Dimitrion, P.; Weiss, M.J.; He, J.; Philosophe, B.; Burkhart, R.; Burns, W.R.; et al. Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. J. Clin. Investig. 2021, 6, 138197. [Google Scholar] [CrossRef]
- Cencic, R.; Carrier, M.; Galicia-Vázquez, G.; Bordeleau, M.-E.; Sukarieh, R.; Bourdeau, A.; Brem, B.; Teodoro, J.G.; Greger, H.; Tremblay, M.L.; et al. Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol. PLoS ONE 2009, 4, e5223. [Google Scholar] [CrossRef] [Green Version]
- Kogure, T.; Kinghorn, A.D.; Yan, I.; Bolon, B.; Lucas, D.M.; Grever, M.R.; Patel, T. Therapeutic Potential of the Translation Inhibitor Silvestrol in Hepatocellular Cancer. PLoS ONE 2013, 8, e76136. [Google Scholar] [CrossRef]
- Gerson-Gurwitz, A.; Young, N.P.; Goel, V.K.; Eam, B.; Stumpf, C.R.; Chen, J.; Fish, S.; Barrera, M.; Sung, E.; Staunton, J.; et al. Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors. Front. Oncol. 2021, 11, 766298. [Google Scholar] [CrossRef]
- Pesce, E.; Miluzio, A.; Turcano, L.; Minici, C.; Cirino, D.; Calamita, P.; Manfrini, N.; Oliveto, S.; Ricciardi, S.; Grifantini, R.; et al. Discovery and Preliminary Characterization of Translational Modulators that Impair the Binding of eIF6 to 60S Ribosomal Subunits. Cells 2020, 9, 172. [Google Scholar] [CrossRef] [Green Version]
- Moerke, N.J.; Aktas, H.; Chen, H.; Cantel, S.; Reibarkh, M.Y.; Fahmy, A.; Gross, J.D.; Degterev, A.; Yuan, J.; Chorev, M.; et al. Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G. Cell 2007, 128, 257–267. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Scagliola, A.; Miluzio, A.; Biffo, S. Translational Control of Metabolism and Cell Cycle Progression in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2023, 24, 4885. https://doi.org/10.3390/ijms24054885
Scagliola A, Miluzio A, Biffo S. Translational Control of Metabolism and Cell Cycle Progression in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2023; 24(5):4885. https://doi.org/10.3390/ijms24054885
Chicago/Turabian StyleScagliola, Alessandra, Annarita Miluzio, and Stefano Biffo. 2023. "Translational Control of Metabolism and Cell Cycle Progression in Hepatocellular Carcinoma" International Journal of Molecular Sciences 24, no. 5: 4885. https://doi.org/10.3390/ijms24054885